Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team


EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has appointed Mr. Adrian Marshall and Mr. James Blakelock to the joint role of Executive Vice President, Corporate Strategy and Planning, and Mr. Bill Wasson to the role of Senior Vice President, Capital Markets and Investor Relations. Working closely with Radient’s existing Management Team and Board of Directors, they will be instrumental in developing, driving and communicating the Company’s corporate strategy and global expansion.

Denis Taschuk, CEO & President of Radient, commented: “These additions to our management team are very strategic in nature, and we consider ourselves fortunate to have attracted such top talent as we move forward with our global expansion plans. Both Mr. Marshall and Mr. Blakelock bring to Radient decades of experience working directly with some of the world’s leading rapid growth consumer products companies, while Mr. Wasson brings his extensive experience in investment banking and corporate advisory, having also been an early mover in corporate financing within the cannabis sector.”

Adrian Marshall, Executive Vice President of Corporate Strategy and Planning

Mr. Marshall is an experienced senior executive and entrepreneur with a wealth of expertise in corporate strategy, international sales & marketing, corporate affairs, and communications. He spent his early career in the beverages, soft paper and tobacco sectors creating & launching new consumer goods brands across markets in the UK, Japan, Russia, the Middle East, and Africa.

Mr. Marshall was the first global head of Corporate Social Responsibility to be appointed by a major tobacco group, British American Tobacco (“BAT”). As Director of BAT’s global ‘harm-reduction’ programme, he was the architect of the group’s strategy to research, develop, assess and commercialize new alternative products such as smokeless tobacco, electronic cigarettes and nicotine inhalers.

After leading BAT’s global harm-reduction efforts for 5 years, Mr. Marshall launched Nicoventures Ltd, a new UK healthcare start-up within the BAT group. Under his leadership, Nicoventures was the first, and to date the only, company to succeed in obtaining a Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a novel nicotine inhalation product with general sale list classification and the harm reduction label, “a safer alternative to smoking.”

Mr. Marshall has started several companies of his own in the technology, marketing, communications and consultancy fields. He holds a BSc. (Hons) in Philosophy from the University of Hull and is an experienced executive leadership coach.

James Blakelock, Executive Vice President of Corporate Strategy and Planning

Prior to joining Radient, Mr. Blakelock worked for 26 years with BAT where he acquired significant international sales, marketing, and country management experience in the United Arab Emirates, Saudi Arabia, Singapore, Cambodia, and Russia. 

Mr. Blakelock held numerous senior executive roles within the BAT Group including Global Head of Regulation, Global Head of Sustainability, Regional Corporate and Regulatory Affairs Director for Eastern Europe, the Middle East, and Africa, and served as a Director of BAT Malaysia Plc.

Mr. Blakelock was responsible for leading BAT’s global regulatory engagement activities, BAT’s successful listing as the only tobacco company in the Dow Jones Sustainability Index, leading the international roll-out of BAT’s award winning social and environmental reporting initiative, and the development of BAT’s global corporate business principles.

He holds a BA (Hons) in Business Studies, a diploma from the Chartered Institute of Marketing, and was recently awarded the Financial Times Non-Executive Director diploma.

William (Bill) Wasson, Senior Vice President, Capital Markets and Investor Relations

Mr. Wasson is a seasoned finance professional with over 25 years of experience providing corporate debt, equity, and advisory services to a wide variety of private and public entities.

Prior to joining Radient, he held senior management roles in corporate credit, investment banking, and private equity. Through his previous roles at TD Bank, National Bank, and multiple boutique dealers, Mr. Wasson has helped finance some of Canada’s largest corporate entities. Additionally, he has fostered groundbreaking financing initiatives in the renewable power, infrastructure, and cannabis sectors in Canada.

Mr. Wasson graduated from McMaster University with a Bachelor of Commerce, and he holds a Chartered Director designation from The Directors College at the DeGroote School of Business.

As Senior Vice President, Capital Markets and Investor Relations for Radient, and subject to approval from the TSX Venture Exchange, Mr. Wasson will be working alongside Radient’s Management Team and Board of Directors to communicate directly with investors, analysts, and shareholders regarding publicly disclosed information pertaining to the Company. He will also be advising the Company on various capital markets strategies, including analyzing potential mergers and acquisitions opportunities on behalf of Radient.   

Shares for Services:

The Company intends to issue shares to a company controlled by Messrs. Marshall and Blakelock as compensation for their corporate strategy and planning services. Pursuant to the terms of the agreement, Radient may issue £48,750 of common shares a month in consideration for such services.

The number of shares to be issued for each month will be determined at the end of each month, after the services have been provided to the Company. The issue price of the shares will be the greater of (i) the 15 day VWAP of Radient shares on the last trading day of such month; and (ii) the “Discounted Market Price” (as defined in the TSX Venture Exchange policies) on the last trading day of such month. Further, if certain revenue milestones are reached by Radient as a result of the services provided by Messrs. Marshall and Blakelock, Radient shall issue additional shares as consideration for the services of Messrs. Marshall and Blakelock. The Company will issue a press release after each issuance of shares under the terms of the Agreement.

The agreement shall automatically renew for successive one-year terms, subject to the rights of termination of the parties. The shares for services agreement is subject to approval by the TSX Venture Exchange and will be subject to TSX Venture Exchange approval for each renewal term.

Proposed Shares for Debt Transaction:

Radient also announces a proposed shares-for-debt transaction in which Radient would issue up to 96,252 common shares, at a price of CAD $1.02 per share, to an arm's length third party creditor of the Company in connection with the settlement of an aggregate of USD $73,206 of debt. The shares for debt transaction is conditional on TSX Venture Exchange approval. All securities to be issued pursuant to this settlement will be subject to a 4-month hold period.

About Radient 
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its MAP™ platform to provide premium ingredients that contain a full range of cannabinoid and terpene profiles. Please visit for more information.

SOURCE: Radient Technologies Inc.

Denis Taschuk, Chief Executive Officer:,
(780) 465-1318;  

Prakash Hariharan, Chief Financial Officer:,
(416) 561-9461 

For press and media enquiries, please contact Caitlin Cheadle, Director of Communications:

For investment enquiries, please contact Bill Wasson, Senior VP of Capital Markets and Investor Relations:

Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the impact of managerial appointments; the shares for services arrangements; the shares for debt proposal; Company’s ability to expand its operations in Europe and Canada; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CESTPress release

Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be

Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio16.7.2019 10:52:00 CESTPress release

MANCHESTER, United Kingdom, July 16, 2019 (GLOBE NEWSWIRE) -- Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics. Specifically, Epistem aims to help customers define whether there are reasons to suspect that there may be human toxicity issues. This will allow better prioritisation of lead compounds, with customers able to make early decisions on whether to abandon, identify alternatives, or develop mitigation strategies for any drugs with human toxicity. Organoids are adult stem cell patient or animal derived structures. Organoids are genetically stable and maintain epithelial functionality in the laboratory. The expanding

Bombardier’s Multi-Award-Winning Global 7500 Jet Reaches New Heights in the Heart of the Swiss Alps15.7.2019 19:00:00 CESTPress release

Global 7500 aircraft is the most spacious purpose-built business jet to operate out of Gstaad’s Saanen airport in Switzerland, where it was on display earlier this month before flying to Dubai, performing another exceptional long-range mission Mission highlights the Global family’s advanced wing design, which enables them to access challenging airfields with short runways in hot temperatures and/or high altitude locations, giving passengers direct access to the heart of the Swiss Alps all year round The Aviation Week Grand Laureate Global 7500 aircraft, also recently recognized as Business Jet of the Year in Robb Report’s Best of the Best 2019, offers Bombardier’s signature smooth ride and a spaciousness that is unique among business jets Bombardier’s Challenger 350 aircraft, also recognized as the Best of the Best Super Mid-size Aircraft by Robb Report, joined the Global 7500 jet on display in Gstaad and achieved a speed record, reaching Malaga in 2 hours and 4 minutes MONTREAL, July

Brookfield Asset Management 2019 Second Quarter Results Conference Call and Webcast15.7.2019 18:27:00 CESTPress release

Date: Thursday, August 8, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, July 15, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2019 Second Quarter Conference Call & Webcast on Thursday, August 8, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 8258617) at approximately 10:50 a.m. The Conference Call will also b

Virtusa Achieves AWS Life Sciences Competency Status15.7.2019 16:01:00 CESTPress release

Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics. Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS.

LGC Capital, Ltd., announces Trichomed received its cultivation license from Health Canada for its new cannabis facility in Brownsburg, Quebec15.7.2019 15:28:00 CESTPress release

MONTREAL, July 15, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) LGC Capital Ltd. (“LGC” or the “Company”), announces that Health Canada, on July 12th, awarded Trichomed Corporation (Trichomed), its long awaited license to cultivate cannabis seeds and plants at its newly constructed facility in Brownsburg, Quebec. As per the terms of its agreement with Trichomed, LGC is, now entitled to convert the first ranking secured loan it provided to Trichomed in December 2017 into a 49% direct equity interest, and a five percent (5%) royalty of Trichomed’s net sales of cannabis and cannabis-related prodcuts which covers actual sales less any arm’s length third-party discounts, merchandise returns and rebates. In addition as per the agreement, LGC is entitled to representation on Trichomed’s board. For further information, please contact: John McMullen, President Tel: (416) 803-0698 Mark Shinners, Chief Financial Officer Tel: +44 7827 960971 mark@lgc-ca